Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 2
2016 3
2017 1
2018 1
2019 2
2020 4
2021 9
2022 5
2023 7
2024 1
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Editorial: COVID-19: From bedside to follow-up.
Gunst JD, Cajander S. Gunst JD, et al. Front Med (Lausanne). 2023 Feb 22;10:1155049. doi: 10.3389/fmed.2023.1155049. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36910496 Free PMC article. No abstract available.
Host Receptor Targeting to Treat Covid-19.
Gunst JD, Søgaard OS. Gunst JD, et al. NEJM Evid. 2023 Nov;2(11):EVIDe2300222. doi: 10.1056/EVIDe2300222. Epub 2023 Oct 24. NEJM Evid. 2023. PMID: 38320534
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity.
Rosás-Umbert M, Gunst JD, Pahus MH, Olesen R, Schleimann M, Denton PW, Ramos V, Ward A, Kinloch NN, Copertino DC, Escribà T, Llano A, Brumme ZL, Brad Jones R, Mothe B, Brander C, Fox J, Nussenzweig MC, Fidler S, Caskey M, Tolstrup M, Søgaard OS. Rosás-Umbert M, et al. Among authors: gunst jd. Nat Commun. 2022 Oct 29;13(1):6473. doi: 10.1038/s41467-022-34171-2. Nat Commun. 2022. PMID: 36309514 Free PMC article.
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.
Gunst JD, Højen JF, Pahus MH, Rosás-Umbert M, Stiksrud B, McMahon JH, Denton PW, Nielsen H, Johansen IS, Benfield T, Leth S, Gerstoft J, Østergaard L, Schleimann MH, Olesen R, Støvring H, Vibholm L, Weis N, Dyrhol-Riise AM, Pedersen KBH, Lau JSY, Copertino DC Jr, Linden N, Huynh TT, Ramos V, Jones RB, Lewin SR, Tolstrup M, Rasmussen TA, Nussenzweig MC, Caskey M, Reikvam DH, Søgaard OS. Gunst JD, et al. Nat Med. 2023 Oct;29(10):2547-2558. doi: 10.1038/s41591-023-02547-6. Epub 2023 Sep 11. Nat Med. 2023. PMID: 37696935 Free PMC article. Clinical Trial.
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.
Gunst JD, Pahus MH, Rosás-Umbert M, Lu IN, Benfield T, Nielsen H, Johansen IS, Mohey R, Østergaard L, Klastrup V, Khan M, Schleimann MH, Olesen R, Støvring H, Denton PW, Kinloch NN, Copertino DC, Ward AR, Alberto WDC, Nielsen SD, Puertas MC, Ramos V, Reeves JD, Petropoulos CJ, Martinez-Picado J, Brumme ZL, Jones RB, Fox J, Tolstrup M, Nussenzweig MC, Caskey M, Fidler S, Søgaard OS. Gunst JD, et al. Nat Med. 2022 Nov;28(11):2424-2435. doi: 10.1038/s41591-022-02023-7. Epub 2022 Oct 17. Nat Med. 2022. PMID: 36253609 Free PMC article. Clinical Trial.
Identifying risk factors for blood culture negative infective endocarditis: An international ID-IRI study.
Filiz M, Erdem H, Ankarali H, Puca E, Ruch Y, Santos L, Fasciana T, Giammanco AM, Ghanem-Zoubi N, Argemi X, Hansmann Y, Guner R, Tonziello G, Mazzucotelli JP, Como N, Kose S, Batirel A, Inan A, Tulek N, Pekok AU, Khan EA, Iyisoy A, Meric-Koc M, Kaya-Kalem A, Martins PP, Hasanoglu I, Silva-Pinto A, Oztoprak N, Duro R, Almajid F, Dogan M, Dauby N, Gunst JD, Tekin R, Konopnicki D, Petrosillo N, Bozkurt I, Al Ramahi JW, Popescu C, Balkan II, Ozer-Balin S, Zupanc TL, Cascio A, Dumitru IM, Erdem A, Ersoz G, Tasbakan M, Ajamieh OA, Sirmatel F, Florescu S, Gulsun S, Ozkaya HD, Sari S, Tosun S, Avci M, Cag Y, Celebi G, Sagmak-Tartar A, Karakus S, Sener A, Dedej A, Oncu S, Del Vecchio RF, Ozturk-Engin D, Agalar C. Filiz M, et al. Among authors: gunst jd. New Microbes New Infect. 2024 Jul 14;60-61:101453. doi: 10.1016/j.nmni.2024.101453. eCollection 2024 Aug-Oct. New Microbes New Infect. 2024. PMID: 39109072 Free PMC article.
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.
Gunst JD, Gohil J, Li JZ, Bosch RJ, White Catherine Seamon A, Chun TW, Mothe B, Gittens K, Praiss L, De Scheerder MA, Vandekerckhove L, Escandón K, Thorkelson A, Schacker T, SenGupta D, Brander C, Papasavvas E, Montaner LJ, Martinez-Picado J, Calin R, Castagna A, Muccini C, de Jong W, Leal L, Garcia F, Gruters RA, Tipoe T, Frater J, Søgaard OS, Fidler S. Gunst JD, et al. Nat Commun. 2025 Jan 21;16(1):906. doi: 10.1038/s41467-025-56116-1. Nat Commun. 2025. PMID: 39837813 Free PMC article.
Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
Breining P, Frølund AL, Højen JF, Gunst JD, Staerke NB, Saedder E, Cases-Thomas M, Little P, Nielsen LP, Søgaard OS, Kjolby M. Breining P, et al. Among authors: gunst jd. Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):204-212. doi: 10.1111/bcpt.13533. Epub 2020 Nov 22. Basic Clin Pharmacol Toxicol. 2021. PMID: 33176395 Free article. Review.
41 results